Imugene Ltd - Asset Resilience Ratio
Imugene Ltd (IMU) has an Asset Resilience Ratio of 23.07% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Imugene Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1995–2025)
This chart shows how Imugene Ltd's Asset Resilience Ratio has changed over time. See IMU net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Imugene Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMU stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$14.14 Million | 20.89% |
| Short-term Investments | AU$1.47 Million | 2.18% |
| Total Liquid Assets | AU$15.61 Million | 23.07% |
Asset Resilience Insights
- Good Liquidity Position: Imugene Ltd maintains a healthy 23.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Imugene Ltd Industry Peers by Asset Resilience Ratio
Compare Imugene Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Imugene Ltd (1995–2025)
The table below shows the annual Asset Resilience Ratio data for Imugene Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 2.49% | AU$2.08 Million ≈ $1.47 Million |
AU$83.59 Million ≈ $59.14 Million |
-31.20pp |
| 2024-06-30 | 33.69% | AU$51.01 Million ≈ $36.09 Million |
AU$151.40 Million ≈ $107.12 Million |
+8.55pp |
| 2023-06-30 | 25.14% | AU$49.54 Million ≈ $35.05 Million |
AU$197.06 Million ≈ $139.43 Million |
+5.49pp |
| 2022-06-30 | 19.65% | AU$29.00 Million ≈ $20.52 Million |
AU$147.61 Million ≈ $104.44 Million |
-9.60pp |
| 2021-06-30 | 29.25% | AU$21.00 Million ≈ $14.86 Million |
AU$71.81 Million ≈ $50.81 Million |
-9.10pp |
| 2020-06-30 | 38.34% | AU$25.00 Million ≈ $17.69 Million |
AU$65.20 Million ≈ $46.14 Million |
-17.52pp |
| 2019-06-30 | 55.87% | AU$17.20 Million ≈ $12.17 Million |
AU$30.78 Million ≈ $21.78 Million |
+9.62pp |
| 2018-06-30 | 46.25% | AU$7.82 Million ≈ $5.53 Million |
AU$16.91 Million ≈ $11.97 Million |
+8.27pp |
| 2017-06-30 | 37.97% | AU$4.81 Million ≈ $3.41 Million |
AU$12.68 Million ≈ $8.97 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$9.54 Million ≈ $6.75 Million |
-- |
| 1996-06-30 | 4.18% | AU$387.00K ≈ $273.83K |
AU$9.25 Million ≈ $6.54 Million |
+0.33pp |
| 1995-06-30 | 3.86% | AU$460.00K ≈ $325.48K |
AU$11.93 Million ≈ $8.44 Million |
-- |
About Imugene Ltd
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA,… Read more